drugset
drugset / Trial / NCT01030055

Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors

NCT01030055 ↗

Phase 1 Completed 60 enrolled Novartis Pharmaceuticals
Non-randomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor

Timeline

Start
2010-02
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule — Oral

Indications

cancer